Allergan said on Monday its oral migraine drug met the main goal across all doses in a study, having a statistically significant reduction in monthly headache days in patients with episode migraines.
The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly in addition to Alder Biopharmaceuticals in which target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP).
Last month, the US Food in addition to Drug Administration approved Amgen’s CGRP treatment Aimovig, which can be self injected monthly in addition to will have a list cost of $6,900 a year, or $575 a month.
Questions have been raised about Amgen’s strategy for Aimovig after the nation’s largest manager of prescription benefits, Express Scripts, told Reuters in which can be pressing Amgen in addition to rival makers of brand new migraine-preventing drugs to reconsider the usual strategy of high list prices in addition to hefty rebates.
Allergan, which aims to bring the first oral CGRP to the market, has two such drugs in its pipeline.
Last month, the company reported positive results form a second late-stage trial for the 50 milligram dose of its additional migraine drug ubrogepant.